Abstract：
:Non-small cell lung cancer (NSCLC) represents almost three quarters of all cases of lung cancer. Most NSCLC patients present with either locally advanced inoperable disease, stage IV metastatic disease, or comorbid medical conditions that make them unsuitable for curative resection. Among NSCLC patients in the United States, overall 5-year survival rates range from 10% to 15%. Systemic chemotherapy has had minimal impact on prolonging survival or improving quality of life. Combination chemotherapy regimens containing cisplatin usually produce the best overall response rates. Combination chemotherapy in one study also has been shown to be more efficacious and less expensive than best supportive care. Newer cytotoxic agents, including vinorelbine, gemcitabine, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), docetaxel, and the camptothecins, have shown promise in the treatment of NSCLC. In combination with other effective agents (eg, cisplatin), response rates approaching 50% have been observed. A greater understanding of the biologic properties of lung cancer may help facilitate early detection and chemoprevention in patients at risk.
journal_name
Semin Oncoljournal_title
Seminars in oncologyauthors
Carney DNsubject
Has Abstractpub_date
1995-08-01 00:00:00pages
58-62issue
4 Suppl 9eissn
0093-7754issn
1532-8708journal_volume
22pub_type
杂志文章,评审abstract：:Choices of treatment for patients with estrogen receptor (ER) positive metastatic breast cancer refractory to first-line endocrine therapies include progestins, antiadrenal drugs, and androgens. These treatments should be administered sequentially to achieve maximum palliation of the disease. For ER positive patients ...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：
更新日期：1988-06-01 00:00:00
abstract：:Traditionally, medical oncology has focused on the active period of diagnosis, treatment and follow-up of cancer patients, and palliative medicine, the pre-terminal and end-of-life phases. Palliative medicine physicians have particular expertise in communication and symptom control, especially, for example, with pain ...
journal_title：Seminars in oncology
pub_type： 杂志文章
doi：10.1053/j.seminoncol.2011.03.021
更新日期：2011-06-01 00:00:00
abstract：:Denileukin diftitox (ONTAK; Seragen Inc, San Diego, CA) is a fusion protein designed to direct the cytocidal action of diphtheria toxin to cells that overexpress the IL-2 receptor. The human IL-2 receptor exists in three isoforms: low (CD25), intermediate (CD122/CD132), and high (CD25/CD122/CD132) affinity. The high-a...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2005.12.017
更新日期：2006-02-01 00:00:00
abstract：:In a multicenter phase III trial, 267 patients with nonbulky metastatic colorectal cancer who had failed first-line 5-fluorouracil (5-FU) therapy were randomized to receive second-line treatment with either the new topoisomerase agent, irinotecan (Rhône-Poulenc Rorer, Antony, France), or a high-dose infusional 5-FU re...
journal_title：Seminars in oncology
pub_type： 临床试验,杂志文章,多中心研究,随机对照试验
doi：
更新日期：1999-02-01 00:00:00
abstract：:The medical treatment of squamous cell cervical carcinoma is receiving increasing attention. Cisplatin and ifosfamide are known effective drugs. Paclitaxel has been tested with interesting results in cervical cancer. We evaluated the toxic effects and the antitumor activity of a multiagent regimen that included paclit...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：
更新日期：2000-02-01 00:00:00
abstract：:It has been a challenge to find effective chemotherapeutic treatments for malignant mesothelioma. Over the last several decades numerous single-drug and combination regimens have been examined, but no standard treatment with chemotherapy alone has emerged. Possible explanations for this lack of success are the heterog...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/sonc.2002.30231
更新日期：2002-02-01 00:00:00
abstract：:A dose-response relationship has long been suspected for progestin compounds in the treatment of breast cancer, but only recently have trials been implemented to investigate this issue. In 1985, we began a phase I-II study of high-dose megestrol acetate in dosages of 480 mg/d to 1,600 mg/d in heavily pretreated postme...
journal_title：Seminars in oncology
pub_type： 杂志文章
doi：
更新日期：1988-04-01 00:00:00
abstract：:Advances in technology have accelerated the translation of genetics and genomics into the arena of cancer prevention. This provides unique opportunities to individualize cancer risk prediction so early intervention can either modify risk or allow for early diagnosis thereby potentially decreasing the morbidity and mor...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2010.05.005
更新日期：2010-08-01 00:00:00
abstract：:Patients diagnosed with germ cell tumors (GCT) are relatively young, and most are rendered disease-free by primary treatment. Also, second-line therapies in nearly all instances are potentially curative. Therefore, the schedule and modalities of follow-up testing are important issues in detecting recurrence of GCT and...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1016/s0093-7754(03)00098-8
更新日期：2003-06-01 00:00:00
abstract：:Etoposide phosphate (Etopophos; Bristol-Myers Squibb Company, Princeton, NJ) is a water-soluble prodrug of etoposide that is converted in vivo by endogenous phosphatases to the active drug etoposide. This conversion process is efficient and not saturable in humans at doses between 50 and 1,600 mg/m2. The resultant eto...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：
更新日期：1996-12-01 00:00:00
abstract：:From February 1985 to June 1993, 173 consecutive, previously untreated patients with small cell lung cancer received individualized treatment tailored to disease extent. Almost all patients (14 of 16) with stage I and II disease and 30 patients with operable stage III disease were submitted to surgery preceded or foll...
journal_title：Seminars in oncology
pub_type： 杂志文章
doi：
更新日期：1995-02-01 00:00:00
abstract：:Immune checkpoint molecules cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1), but also LAG-3 and TIM-3, are involved in regulation of peripheral tolerance in order to prevent autoimmunity. Blocking of these cell surface proteins by antibodies has resulted in remarkable anti-tumor immunity; howev...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2015.02.011
更新日期：2015-06-01 00:00:00
abstract：:We report an open, three-armed, multicenter study being carried out to assess the optimum treatment for acute and delayed emesis and nausea in patients undergoing highly emetogenic chemotherapy. Eighty-seven patients were randomized to receive tropisetron (Navoban; Sandoz Pharma Ltd, Basel, Switzerland), tropisetron p...
journal_title：Seminars in oncology
pub_type： 临床试验,杂志文章,多中心研究,随机对照试验
doi：
更新日期：1994-10-01 00:00:00
abstract：:Cyclooxygenase (COX) enzyme-dependent arachidonic acid metabolites occupy key positions in important physiologic processes such as immunity, reproduction, and vascular integrity. Large retrospective and prospective population-based studies have shown that the use of both nonselective, nonsteroidal anti-inflammatory dr...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1016/s0093-7754(03)00120-9
更新日期：2003-06-01 00:00:00
abstract：:Almost 125 years after the first documented case, pulmonary metastasectomy is still poorly understood. No other organ is subject to the wide histologic variety of metastatic insults, and this fact has complicated a complete exposition of when pulmonary metastasectomy may be beneficial. Many physicians still consider p...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2007.03.004
更新日期：2007-06-01 00:00:00
abstract：:The use of adjuvant radiation therapy and chemotherapy diminishes the likelihood of local-regional and distant recurrences and appears to prolong survival in patients who have undergone a complete surgical resection of a Dukes-Kirklin stage B2 or C rectal cancer. Patients with this malignant condition rarely develop p...
journal_title：Seminars in oncology
pub_type： 杂志文章
doi：
更新日期：1985-09-01 00:00:00
abstract：:Vinorelbine, a vinca alkaloid, was the first drug in over 20 years to be approved by the Food and Drug Administration for treatment of advanced non-small cell lung cancer (NSCLC). The drug's nonhematologic toxicities are usually mild; its dose-limiting toxicity is neutropenia. Vinorelbine has been studied in many phas...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：
更新日期：1999-10-01 00:00:00
abstract：:The purpose of this pilot study was to determine the safety and feasibility of accelerated fractionation (via concomitant boost) radiotherapy (XRT) with concurrent carboplatin/paclitaxel chemotherapy for locally advanced stage III non-small cell lung carcinoma. Radiotherapy consisted of 3-dimensional conformal techniq...
journal_title：Seminars in oncology
pub_type： 临床试验,杂志文章
doi：10.1053/j.seminoncol.2005.03.004
更新日期：2005-04-01 00:00:00
abstract：:The approval, in 2015, of the first poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi; olaparib, Lynparza) for platinum-sensitive relapsed high-grade ovarian cancer with either germline or somatic BRCA1/2 deleterious mutations is changing the way that BRCA1/2 testing services are offered to patients with...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2017.08.004
更新日期：2017-06-01 00:00:00
abstract：:Transitional cell carcinoma of the urothelium is a highly chemosensitive tumor. Combination chemotherapy can provide both palliation and a modest survival advantage in patients with advanced disease. As shown in a recent phase III trial, the new gold standard should be considered gemcitabine/cisplatin, although toxici...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/sonc.2001.22537
更新日期：2001-06-01 00:00:00
abstract：:Spirituality can exert a tremendous impact on ones health and promote recovery from trauma and illness, including cancer. Throughout the history of mankind, spirituality and religion have played a major role in healing a variety of physical and mental illnesses. Cancer is one of the most devastating illnesses, as it a...
journal_title：Seminars in oncology
pub_type： 杂志文章
doi：10.1053/j.seminoncol.2004.11.017
更新日期：2005-04-01 00:00:00
abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been shown to be an effective agent in the treatment of metastatic breast carcinoma. This multicenter randomized study compared paclitaxel 175 mg/m2 given as a 3-hour infusion every 3 weeks with mitomycin 12 mg/m2 given as an intravenous infusion ever...
journal_title：Seminars in oncology
pub_type： 临床试验,杂志文章,多中心研究,随机对照试验
doi：
更新日期：1995-08-01 00:00:00
abstract：:In two different controlled prospective randomized trials the Lung Cancer Study Group has shown that adjuvant CAP chemotherapy is effective in prolonging the disease-free survival. These studies indicate that the adjuvant chemotherapy has its effect by way of diminishing systemic recurrences and that the adjuvant ther...
journal_title：Seminars in oncology
pub_type： 临床试验,杂志文章,随机对照试验
doi：
更新日期：1988-06-01 00:00:00
abstract：:Single-agent gemcitabine remains the standard treatment for advanced pancreatic cancer. Recent phase III trials have failed to show improvements in survival using gemcitabine in combination with other chemotherapeutic agents, although the gemcitabine/oxaliplatin combination has shown some promise. The combination of g...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2005.06.022
更新日期：2005-08-01 00:00:00
abstract：:Although originally developed as an antitumor agent in the 1970s, dexrazoxane (DEX) is currently used as a cardioprotective agent in combination with doxorubicin (DOX). Due to concerns about anthracycline-induced cardiotoxicity at higher cumulative doses, many investigators have chosen to administer DOX by prolonged i...
journal_title：Seminars in oncology
pub_type： 临床试验,杂志文章
doi：
更新日期：1998-08-01 00:00:00
abstract：:Dry mouth (xerostomia) is one of the most common complaints following radiation therapy (RT) for head and neck cancers. Notably, RT causes irreparable damage to salivary glands that increases the risk for severe and long-term oral and pharyngeal disorders. Several strategies in the treatment of head and neck cancers h...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2004.12.009
更新日期：2004-12-01 00:00:00
abstract：:Anorexia and cachexia are common clinical problems of many patients with advanced cancer. Approximately 20 years ago, a controlled, clinical study demonstrated that dexamethasone could stimulate appetites of patients with advanced gastrointestinal cancer without causing any apparent effect on patient weight or surviva...
journal_title：Seminars in oncology
pub_type： 临床试验,杂志文章,随机对照试验,评审
doi：
更新日期：1990-12-01 00:00:00
abstract：:Acute and chronic graft-versus-host disease (GvHD) remain major obstacles to successful allogeneic hematopoietic stem cell transplantation, contributing substantially to morbidity and non-relapse mortality. Better understanding of the immunopathophysiology of GvHD has identified a number of targets for intervention. A...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1016/s0093-7754(03)00250-1
更新日期：2003-08-01 00:00:00
abstract：:The limited single-agent activity of cisplatin, its toxicity profile, and the inconvenience involved in hydrating patients has compelled researchers to investigate other treatments as possible alternative therapies in non-small cell lung cancer. More recently, interest has focused on the potential of nonplatinum combi...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1016/s0093-7754(01)90299-4
更新日期：2001-02-01 00:00:00
abstract：:The results of recent clinical trials have shown that docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France), like paclitaxel (Taxol; Bristol-Myers Squibb Oncology, Princeton, NJ), has high levels of activity in patients with anthracycline-resistant breast cancer. Agents that are at least partially non-cross-resist...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：
更新日期：1995-12-01 00:00:00
